Immunohistochemical and Clinical Assessment of Low-Risk Thyroid Tumors

Aydoğan B. İ., Hasanov R., YÜKSEL S., SEVİM S., SAK S., Güllü S.

Endocrinology Research and Practice, cilt.27, sa.4, ss.199-204, 2023 (Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 4
  • Basım Tarihi: 2023
  • Doi Numarası: 10.5152/erp.2023.23238
  • Dergi Adı: Endocrinology Research and Practice
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.199-204
  • Anahtar Kelimeler: CD56, galectin-3, HBME-1, Noninvasive follicular thyroid neoplasm with papillary-like nuclear features, well-differentiated neoplasm of uncertain malignant potential
  • Ankara Üniversitesi Adresli: Evet

Özet

Objective: Differential diagnosis and prognosis of low-risk follicular cell-derived thyroid neoplasms have been conflicting. We aimed to evaluate immunohistochemical features and prognosis of tumors in “well-differentiated tumor of uncertain malignant potential” and “noninvasive follicular thyroid neoplasm with papillary-like nuclear features” categories. Methods: Fifty-two low-risk thyroid tumors which were classified as well-differentiated tumor of uncertain malignant potential (n = 23) and noninvasive follicular thyroid neoplasm with papillary-like nuclear features (n = 29) with a follow-up of at least 60 months were included. Galectin-3, HBME-1, CK19, and CD56 expressions were evaluated. The control group included benign nodules (n = 53), conventional papillary thyroid carcinomas (n = 37), and encapsulated follicular variant papillary thyroid carcinomas (n = 60). Results: During a median 84 months follow-up period, none of the patients experienced a recur-rence of tumor. Expression of HBME-1 in low-risk tumors was significantly frequent than benign and infrequent than malignant tumors (P =.001 and P <.001, respectively). The frequency of galectin-3 positivity was similar between low-risk and malignant tumors (P =.805) and significantly higher in low-risk tumors when compared to benign nodules (P <.001). Expression of CK19 in low-risk tumors was significantly frequent than benign nodules and infrequent than malignant tumors (P =.01 and P =.001, respectively). The expression profile of CD56 was similar in benign nodules and low-risk tumors (P =.361). Total loss of CD56 in tumor was the most specific marker of malignancy (100%). Positive staining of HMBE-1 was the most sensitive marker (89.7%) for predicting malignancy. Conclusion: Low-risk thyroid tumors had immunohistochemical features overlapping with both benign and malignant thyroid tumors and had a benign course of disease during a long follow-up period.